Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Meiragtx Holdings ( (MGTX) ) has issued an announcement.
MeiraGTx Holdings plc has received the necessary clearances and approvals under the UK’s foreign direct investment laws for its proposed transactions with Hologen Limited, which were initiated on March 9, 2025. These transactions are anticipated to conclude in July 2025, potentially impacting the company’s operational and strategic positioning in the market.
The most recent analyst rating on (MGTX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Meiragtx Holdings stock, see the MGTX Stock Forecast page.
Spark’s Take on MGTX Stock
According to Spark, TipRanks’ AI Analyst, MGTX is a Neutral.
MeiraGTx Holdings’ score reflects a mix of financial instability typical of early-stage biotech firms and recent strategic advantages. The technical analysis shows bullish momentum, while corporate events provide a significant positive outlook with FDA designation and a strategic joint venture. Valuation remains a concern due to negative earnings.
To see Spark’s full report on MGTX stock, click here.
More about Meiragtx Holdings
Average Trading Volume: 570,269
Technical Sentiment Signal: Buy
Current Market Cap: $525.6M
For a thorough assessment of MGTX stock, go to TipRanks’ Stock Analysis page.